European Union · Question · QUESTION_WRITTEN
E-10-2025-003611
Guidelines for the use of the 2025-2026 formulation of the Comirnaty vaccine (LP.8.1-adapted monovalent COVID-19 vaccine)
Introduced
17 September 2025
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
14 November 2025
Records
Official question E-10-2025-003611 from European Union at European Parliament. Dated 17 September 2025. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
5 official files
Guidance on the use of the 2025-2026 formulation of the Comirnaty vaccine (LP.8.1-adapted monovalent COVID-19 vaccine)
Guidance on the use of the 2025-2026 formulation of the Comirnaty vaccine (LP.8.1-adapted monovalent COVID-19 vaccine)
QUESTION_WRITTEN · EN · 24 September 2025
Guidance on the use of the 2025-2026 formulation of the Comirnaty vaccine (LP.8.1-adapted monovalent COVID-19 vaccine)
QUESTION_WRITTEN · EN · 24 September 2025
Answer
QUESTION_WRITTEN_ANSWER · 14 November 2025
Richtlijnen voor het gebruik van de 2025-2026-formulering van het Comirnaty-vaccin (LP.8.1-aangepast monovalent COVID-19-vaccin)
QUESTION_WRITTEN · NL · 24 September 2025
Richtlijnen voor het gebruik van de 2025-2026-formulering van het Comirnaty-vaccin (LP.8.1-aangepast monovalent COVID-19-vaccin)
QUESTION_WRITTEN · NL · 24 September 2025
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.